Zhejiang Hisun Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kevin Xiao

Chief Executive Officer (CEO)

CN¥869.5k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

Sep 26

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Apr 30

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Mar 29

CEO

Kevin Xiao (55 yo)

1.1yrs

Permanencia

CN¥869,500

Compensación

Mr. Weihong Xiao, also known as Kevin, has been Chief Executive Officer at Zhejiang Hisun Pharmaceutical Co., Ltd. since October 11, 2023. He served as Chief Operating Officer at 3SBio Inc. since March 201...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Weihong Xiao	Chief Executive Officer	1.1yrs	CN¥869.50k	sin datos
Hong Shun Jin	Senior Vice President	5.5yrs	CN¥1.13m	0.018% CN¥ 1.8m
Zhiqing Yang	Senior Vice President	5.5yrs	CN¥1.39m	0.021% CN¥ 2.1m
Jiaqiu Du	Director and Senior Vice President	5.5yrs	CN¥2.13m	0.021% CN¥ 2.1m
Xi Fei Shen	Secretary of the Board	7.1yrs	CN¥825.50k	0.013% CN¥ 1.3m

5.5yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600267 es experimentado (5.5 años antigüedad media).

Zhejiang Hisun Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.031 in 3Q 2023)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

Price target decreased by 10.0% to CN¥6.30

Second quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.18 in 2Q 2023)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Full year 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Investor sentiment deteriorates as stock falls 17%

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Price target decreased by 13% to CN¥8.30

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.01 in 3Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.43 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.19 in 3Q 2021)

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 195 million worth of its shares.

Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million.

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.13 in 2Q 2021)

Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million.

Investor sentiment improved over the past week

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.43 (vs CN¥0.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.074 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.096 in FY 2019)

New 90-day low: CN¥15.49

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: CN¥18.41

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥15.63

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion.

Earnings released

New 90-day high - CN¥18.90

Zhejiang Hisun Pharmaceutical Co., Ltd. announced a financing transaction

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad